Please login to the form below

Not currently logged in
Email:
Password:

Venus secures EU patent for Achnil

Venus Remedies has been granted a patent by the European Patent Office for its research drug Achnil, a once-daily painkiller injection

Venus Remedies has been granted a patent by the European Patent Office (EPO) for its research drug Achnil, a once-daily painkiller injection.

The patent will run until 2025 in the member countries of EPO, reinforcing the market position of Venus Remedies in the major economies such as France, Germany, Italy, Spain, Sweden, and Switzerland and UK.

Dr Manu Chaudhry, joint managing director, said: "This novel formulation based on NDDS (novel drug delivery system) technology is going to fill the gap of long standing demand for better pain management therapy. Especially for aged population, it is not only going to reduce the number of pricks but will also drastically reduce the side effects associated with the use of NSAIDs [non-steroidal anti-inflammatory drugs]."

The development of Achnil took more than five years and has completed phase-III clinical trials successfully.

The company said it has plans to commercialise Achnil formulation in the European market through out-licensing of exclusive marketing rights to a pharma major.

24th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics